NCT01237223 - Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension | Biotech Hunter

Enrollment

1,342

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Essential Hypertension

Interventions

DRUG

Aliskiren/Amlodipine 150/2.5 mg

Aliskiren/amlodipine 150/2.5 mg tablet

DRUG

Aliskiren/amlodipine 150/5 mg

Aliskiren/amlodipine 150/5 mg tablet

DRUG

Aliskiren 150 mg

Aliskiren 150 mg tablet

DRUG

Amlodipine 2.5 mg

Amlodipine 2.5 mg capsule

DRUG

Placebo of Aliskiren

Aliskiren placebo tablet

DRUG

Placebo of Amlodipine

Amlodipine placebo capsule

DRUG

Placebo of Aliskiren/amlodipine 150/2.5 mg

Aliskiren/amlodipine 150/2.5 mg placebo tablet

DRUG

Placebo of Aliskiren/amlodipine 150/5 mg

Aliskiren/amlodipine 150/5 mg placebo tablet

Trial Locations (11)

Unknown

Investigative Site, Aichi

Investigative Site, Ehime

Investigative Site, Fukuoka

Investigative Site, Hokkaido

Investigative Site, Hyōgo

Investigative Site, Kanagawa

Investigative Site, Kyoto

Investigative Site, Okayama

Investigative Site, Osaka

Investigative Site, Saitama

Investigative Site, Tokyo